Listing 3 - Actual negotiations

Indication:

Schizophrenia in Adults

Indication:

Metastatic Colorectal Cancer (mCRC); Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC); Platinum-Sensitive Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; and Malignant Glioma (WHO Grade IV) - Glioblastoma

Indication:

Unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, in adult patients, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options

Indication:

Non-small cell lung cancer (NSCLC) in adult patients whose tumours have PD-L1 expression on ? 50% of tumour cells (TCs) and do not have EGFR or ALK genomic tumour aberrations, monotherapy for adjuvant treatment following resection and platinum-based chemotherapy, Stage II to IIIA (per the American Joint Committee on Cancer [AJCC], 7th edition)

Indication:

Advanced or metastatic breast cancer, Hormone receptor-positive, HER2-negative, PIK3CA mutated, after disease progression following an endocrine-based regimen, in postmenopausal women and men (In combination with fulvestrant)

Indication:

Long-Chain Fatty Acid Oxidation Disorders

Indication:

Asthma

Indication:

Neutropenia in various indications (Prevention or treatment)

Indication:

Diabetic Macular Edema

Indication:

Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) previously treated with two or more tyrosine kinase inhibitors, in adult patients